Synvisc-One® (hylan G-F 20) Medical Study
Knee Pain Assessment
Get the most out of your upcoming doctor’s appointment. Get a free personalized report to help you talk with your doctor.
Start Assessment
Background: A study of Synvisc-One was conducted in 253 patients in six countries outside the United States. Patients were at least 40 years old, had mild or moderate knee OA and were experiencing moderate to severe knee pain. Patients in the study were given either:
- A single injection of Synvisc-One
- An injection of salt water (called a "saline control")
The goal was to determine how well Synvisc-One reduced knee pain during five common activities (walking, going up stairs, etc.). Doctors evaluated the patients at weeks 1, 4, 8, 12, 18 and 26.
Results: The study showed that patients who received Synvisc-One had significantly less pain over six months and felt significantly better than the saline control group. Specifically, 71% of patients reported pain relief with Synvisc-One. Most patients reported pain relief starting at week four.
Side effects were also tracked. The types and frequencies of side effects were similar between the two groups. The most common side effects were knee pain, stiffness, and swelling or fluid buildup in or around the knee. These were generally mild to moderate and did not last long. No serious side effects were seen in the injected knee during the study that were related to the use of Synvisc-One.